Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

8 results

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated as a complete regimen for treating HIV-1 infection in adults and adolescents aged 12 and older (weighing at least 35 kg) who are virologically suppressed and stable on their current antiretroviral therapy, with no treatment failure history or known resistance to its components.

  • complera

    (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.

  • delstrigo

    (doravirine, lamivudine, and tenofovir disoproxil fumarate)
    Merck Sharp & Dohme LLC
    DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment or to replace the current regimen in patients who are virologically suppressed with no history of treatment failure.

  • edurant

    (rilpivirine hydrochloride)
    Janssen Products, LP
    EDURANT is indicated for the treatment of HIV-1 in treatment-naïve patients aged 2 and older with specific viral loads. It is also used in combination with cabotegravir for short-term treatment in adults and adolescents who are virologically suppressed and require an oral lead-in or temporary oral therapy.

  • intelence

    (etravirine)
    Janssen Products LP
    INTELENCE is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults and pediatric patients aged 2 years and older.

  • juluca

    (dolutegravir sodium and rilpivirine hydrochloride)
    ViiV Healthcare Company
    JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.

  • odefsey

    (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    ODEFSEY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) as initial therapy for those with no prior treatment and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically-suppressed patients with specific criteria.

  • pifeltro

    (doravirine)
    Merck Sharp & Dohme LLC
    PIFELTRO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents, either for those with no prior treatment history or to replace a stable regimen in virologically-suppressed patients without treatment failure history.